Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Inc.

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Jasper Therapeutics, with a price target of $7.00. The company’s ...

BTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

William Blair analyst Matt Phipps maintained a Hold rating on Jasper Therapeutics yesterday. The company’s shares closed yesterday at $1.78. Phipps...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JSPR	$1.70	-3.41%	300.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JSPR	$1.70	-3.4%	300.23K
3
4
5
6

JSPR

JSPR

Latest News for JSPR

Get Jasper Therapeutics Inc. Data in Excel

Get Jasper Therapeutics Inc. Data in Excel